The Business of Bioanalysis: New Technology Integration into Bioanalytical Workflows

Summerfield, Scott; Hayes, Roger N.; Liang, Meina; Safavi, Afshin; Warrino, Dominic; Luo, Lina; Moore, I J

doi:10.4155/bio-2018-0269

Cited by 4 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was also the successful publication of Panel Discussions that we organized with the Bioanalysis Zone team, in which experts from leading CROs, consultancies and pharmaceutical companies discussed two current issues facing the bioanalytical field: new technology integration in bioanalytical workflows and the sharing of scientific data. The Panel Discussion Report we published alongside this was also popular among our readership [21].…”

Section: Bioanalysis Zonementioning

confidence: 95%

Welcome to the 11th Volume of Bioanalysis

Finnie

2018

Bioanalysis

View full text Add to dashboard Cite

Welcome to the 11th volume of Bioanalysis and we want to take this opportunity to wish you all a Happy New Year. We would like to take this opportunity to reflect on the past 12 months from the perspective of the journal. We want to thank all our authors, readers and reviewers, as well as our esteemed Editorial Board members for their ongoing support.We are very much looking forward to working with everyone in 2019. Content highlightsBioanalysis continues to publish a wide variety of articles covering key advances within this ever-evolving field and we would like to take this opportunity to reflect on some of our most accessed content of last year, at the time of writing this article (October 2018). One of the most popular articles of this year proved to be the Special Report, ' Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan', which provided the views and recommendations from a Japanese research group on the ADA assay [1].As in 2017, meeting reports feature highly among our most popular content of 2017. One of the most-read articles was the Conference Report from the 11th GCC closed forum [2], the objective of which was for CRO bioanalytical representatives to meet and discuss scientific and regulatory issues specific to bioanalysis. Similarly, 'Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles' was also one of the most popular conference reports from this year [3].Several editorial-style articles providing a snapshot of issues of topical importance to the bioanalytical community featured in our most read content. Some novel approaches were explored this year, including: ' Machine learning techniques for mass spectrometry imaging data analysis and applications', an Editorial by Zhang and Liu [4], while Devangi Mehta, Shobha Purushothama and Lauren Stevenson explored ' Parallelism: the foundation of biomarker assay development and validation' in their Editorial [5].We have continued to publish a range of exciting research-style articles presenting novel work and representing important advancement in understanding of techniques, which continue to be highly accessed. Examples of these include the Methodology article on the 'Evaluation of cAMS for 14 C microtracer ADME studies: opportunities to change the current drug development paradigm' [6] and a Research Article exploring a 'Novel and rapid LC-MS/MS method for quantitative analysis of methylphenidate in dried blood spots' [7]. A Perspective article exploring the importance of 'Biomarkers in early-phase trials: fundamental issues' [8] was one of the most viewed review-style pieces. These aim to highlight recent significant advances in research, ongoing challenges and unmet needs within the field.As we enter 2019, we will endeavor to continue capturing the trends and evolution of the field of bioanalysis.

show abstract

Section: Bioanalysis Zonementioning

confidence: 95%

Welcome to the 11th Volume of Bioanalysis

Finnie

2018

Bioanalysis

View full text Add to dashboard Cite

show abstract

“…Immunogenicity assessment may require more explicit evaluation of the intact molecule, each function domain, linkers, the degraded form, metabolites, and the combination thereof. While the continued demand for greater sensitivity, selectivity, detectability, drug tolerance, speed, and cost efficiency is driving the development of new tools such as ultrasensitive and multiplex equipment, a balance needs to be achieved between the use of new and current approaches in the absence of regulatory guidance on the former in order to mitigate the risks carried forward on critical aspects such as data quality, data comparability, and data integrity (92,93). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.…”

Section: Summary and Future Perspectivementioning

confidence: 99%

Bioanalysis in the Age of New Drug Modalities

Shi

Chen

Diao

et al. 2021

AAPS J

View full text Add to dashboard Cite

In the absence of regulatory guidelines for the bioanalysis of new drug modalities, many of which contain multiple functional domains, bioanalytical strategies have been carefully designed to characterize the intact drug and each functional domain in terms of quantity, functionality, biotransformation, and immunogenicity. The present review focuses on the bioanalytical challenges and considerations for RNA-based drugs, bispecific antibodies and multi-domain protein therapeutics, prodrugs, gene and cell therapies, and fusion proteins. Methods ranging from the conventional ligand binding assays and liquid chromatography-mass spectrometry assays to quantitative polymerase chain reaction or flow cytometry often used for oligonucleotides and cell and gene therapies are discussed. Best practices for method selection and validation are proposed as well as a future perspective to address the bioanalytical needs of complex modalities.

show abstract

Application and Effectiveness Evaluation of Augmented Reality Technology in History Museum Exhibitions

Yang

2024

Applied Mathematics and Nonlinear Sciences

View full text Add to dashboard Cite

In the context of the rapid evolution of science and technology, the integration of reality technologies has become indispensable for the evolution of history museum exhibitions towards digitization, connectivity, and intelligence. This study details the development of a visual-inertial guidance system, leveraging both the Inertial Measurement Unit (IMU) and Simultaneous Localization and Mapping (SLAM) technologies. To construct a mixed reality tour guide system, the Scale Invariant Feature Transform (SIFT) feature extraction algorithm and tracking registration technology were employed to enhance the system’s exhibit recognition accuracy and tracking capabilities. Additionally, parallel processing techniques were implemented to accelerate the system’s performance, thereby improving operational efficiency while maintaining accuracy and maximizing the potential of augmented reality interactive functions within the history museum setting. The effectiveness of the system was empirically validated through participant evaluations across three dimensions: task completion, design recognition, and knowledge conveyance. Results indicate that all average scores exceeded 9, with 85% of participants acknowledging the enhanced convenience in knowledge acquisition provided by the technology. Furthermore, the coefficients for the guided tour abstract symbol verification were recorded at -0.007, 0.009, and 0.081, respectively. These findings corroborate that the deployment of an augmented reality interactive system and a mixed reality tour system can significantly expand the public service functions and historical-cultural education offerings of history museum exhibitions while also enriching the sensory experiences of attendees.

show abstract

The Business of Bioanalysis: New Technology Integration into Bioanalytical Workflows

Cited by 4 publications

References 8 publications

Welcome to the 11th Volume of Bioanalysis

Welcome to the 11th Volume of Bioanalysis

Bioanalysis in the Age of New Drug Modalities

Application and Effectiveness Evaluation of Augmented Reality Technology in History Museum Exhibitions

Contact Info

Product

Resources

About